Gianella A.,Mount Sinai School of Medicine |
Gianella A.,Cardiology Monzino Center |
Jarzyna P.A.,Mount Sinai School of Medicine |
Mani V.,Mount Sinai School of Medicine |
And 10 more authors.
ACS Nano | Year: 2011
Nanoparticle applications in medicine have seen a tremendous growth in the past decade. In addition to their drug targeting application and their ability to improve bioavailability of drugs, nanoparticles can be designed to allow their detection with a variety of imaging methodologies. In the current study, we developed a multimodal nanoparticle platform to enable imaging guided therapy, which was evaluated in a colon cancer mouse model. This "theranostic" platform is based on oil-in-water nanoemulsions and carries iron oxide nanocrystals for MRI, the fluorescent dye Cy7 for NIRF imaging, and the hydrophobic glucocorticoid prednisolone acetate valerate (PAV) for therapeutic purposes. Angiogenesis-targeted nanoemulsions functionalized with αvβ3-specific RGD peptides were evaluated, as well. When subcutaneous tumors were palpable, the nanoemulsions were administered at a dose of 30 mg of FeO/kg and 10 mg of PAV/kg. MRI and NIRF imaging showed significant nanoparticle accumulation in the tumors, while tumor growth profiles revealed a potent inhibitory effect in all of the PAV nanoemulsion-treated animals as compared to the ones treated with control nanoemulsions, the free drug, or saline. This study demonstrated that our nanoemulsions, when loaded with PAV, iron oxide nanocrystals, and Cy7, represent a flexible and unique theranostic nanoparticle platform that can be applied for imaging guided therapy of cancer. © 2011 American Chemical Society.
Baldassarre D.,University of Milan |
Baldassarre D.,Cardiology Monzino Center |
Werba J.P.,Cardiology Monzino Center |
Castelnuovo S.,University of Milan |
And 7 more authors.
Atherosclerosis | Year: 2010
Objective: To assess whether the diagnosis 'metabolic syndrome' (MS) predicts the degree of subclinical atherosclerosis better than its component parts or the total number of vascular risk factors (VRFs) in patients attending a lipid clinic. Methods: Carotid intima-media thickness (C-IMT) was measured by B-mode ultrasound in 1804 patients (56 ± 13 years; 52% women). To investigate whether the increased subclinical carotid atherosclerosis often ascribed to MS may be explained by a real interaction between the components or simply by a sum of VRFs, observed C-IMTs were compared with those predicted by the sum of individual components. Values for C-IMT of MS patients were also compared with those of controls matched for number of VRFs or for SCORE predicted risk (SPR). Results: Carotid IMT values were significantly higher in patients with MS (n=362) than in those not so diagnosed (IMTmean, 1.07±0.37 vs. 0.95±0.33; IMTmax, 1.98±0.93mm vs. 1.67±0.82mm, both p<0.0001), but were not higher than those predicted by the sum of individual risk factors. The linear regression lines of the correlations between C-IMT and total number of VRFs overlapped in patients with and without MS. In patients with and without MS matched for age, sex and total number of VRFs, or matched for age, sex and SPR the C-IMT differences disappeared. Conclusions: In patients attending a lipid clinic, 'metabolic syndrome' appears not to correlate with C-IMT to a greater extent than what is expected from its component parts or from the patient's total number of VRFs. © 2010 Elsevier Ireland Ltd.